However, whether HER2 and MET are co-expressed has not yet been fully studied in Chinese GC patients, and whether the combination of HER2 and MET targeted therapies can synergistically inhibit tumor growth has not been well established. This evidence concerns the gene ERBB2 and gastric cancer.